ECDC - Rapid risk assessment: Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 15th update

ECDC - Rapid risk assessment: Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 15th update

European Centre for Disease Prevention and ControlAlthough SARS-CoV-2 transmission remains widespread in large parts of the EU/EEA, most countries report declining trends in 14-day COVID-19 notification rates, hospital and intensive care unit...
ECDC - Countering online vaccine misinformation in the EU/EEA

ECDC - Countering online vaccine misinformation in the EU/EEA

European Centre for Disease Prevention and ControlVaccines authorised by the European Medicines Agency for use in the European Union (EU) are known to be safe and effective in preventing infectious diseases. Nonetheless, misinformation that...
JAMA - SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women

JAMA - SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women

JAMA NETWORKOn December 20, 2020, Israel initiated a national vaccination program against COVID-19. One prioritized group was health care workers, many of whom are breastfeeding women. Despite the fact that the vaccine trial did not include...
NEJM - Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

NEJM - Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

The New England Journal of MedicineThe B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a surge in cases in India and has...
BMJ - Covid-19 vaccines for children: hypothetical benefits to adults do not outweigh risks to children

BMJ - Covid-19 vaccines for children: hypothetical benefits to adults do not outweigh risks to children

British Medical JournalAs the majority of adults in multiple rich western countries have now received at least one dose of a covid-19 vaccine, the focus is turning to children. While there is wide recognition that children’s risk of severe...
NEJM - Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

NEJM - Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

The New England Journal of MedicineInformation is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome...
ECDC - Considerations for the use of saliva as sample material for COVID-19 testing

ECDC - Considerations for the use of saliva as sample material for COVID-19 testing

European Centre for Disease Prevention and Control

Nasopharyngeal specimens remain the gold standard for COVID-19 testing for use with RT-PCR and rapid antigen diagnostic tests.

ECDC - Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings

ECDC - Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings

European Centre for Disease Prevention and ControlThe use of rapid antigen detection tests (RADTs) and/or self-test RADTs in occupational settings can complement, but not replace, occupational safety and health measures and existing...
ECDC - Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities

ECDC - Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities

European Centre for Disease Prevention and ControlThe main aim of this activity is to collect information on the severity of breakthrough COVID-19 infections in outbreaks, by SARS-CoV-2 variant and vaccine product. This activity is not intended...
ECDC - Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA

ECDC - Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA

European Centre for Disease Prevention and Control

This report provides an updated overview of the progress of national COVID-19 vaccination strategies in EU/EEA countries.

ECDC - Objectives of vaccination strategies against COVID-19

ECDC - Objectives of vaccination strategies against COVID-19

European Centre for Disease Prevention and Control

This document provides an overview of the possible goals of vaccination against COVID-19 and reflects on potential implications.

ECDC - Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions

ECDC - Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions

European Centre for Disease Prevention and ControlCOVID-19 vaccines licensed in the EU/EEA have been shown during clinical trials to be highly effective in providing protection against symptomatic and severe COVID-19. Evidence from real-life...
NEJM - Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

NEJM - Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

The New England Journal of MedicineSeveral cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome...
NEJM - Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

NEJM - Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

The New England Journal of MedicineWe report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus...
NEJM - On the Shoulders of Giants — From Jenner’s Cowpox to mRNA Covid Vaccines

NEJM - On the Shoulders of Giants — From Jenner’s Cowpox to mRNA Covid Vaccines

The New England Journal of MedicineIn December 2020, on the basis of safety and efficacy data generated in two large, placebo-controlled studies, the Food and Drug Administration (FDA) issued emergency use authorizations for two mRNA vaccines for...
1234
Eventos
«setembro de 2021»
segterquaquisexsábdom
303112345
6789101112
13141516171819
20212223242526
2728
Dia 28 de setembro às 17h00

Dia 28 de setembro às 17h00

A chill out session prevista para dia 24 de setembro ao fim da tarde foi adiada, tendo em conta a previsão meteorológica. Assim, passará a realizar-se no dia 28 de setembro, a partir das 17h00, no Jardim da Ordem dos Médicos, em Lisboa. A sessão inclui uma apresentação da médica e cantora Catarina Munhá, a partir das 18h00.

Ler mais
2930123
45678910
Categorias

Categorias

Arquivo de Notícias

Arquivo